| Literature DB >> 15286708 |
Khalid Bajou1, Catherine Maillard, Maud Jost, Roger H Lijnen, Ann Gils, Paul Declerck, Peter Carmeliet, Jean-Michel Foidart, Agnès Noel.
Abstract
Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells (transgenic mice overexpressing PAI-1) or by tumor cells (after transfection with murine PAI-1 cDNA). This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15286708 DOI: 10.1038/sj.onc.1207859
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867